Stoke Therapeutics Inc (STOK) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Stoke Therapeutics Inc (STOK) has a cash flow conversion efficiency ratio of -0.164x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-56.59 Million) by net assets ($345.55 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Stoke Therapeutics Inc stock valuation for the company's overall valuation and market capitalisation.
Stoke Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2017–2025)
This chart illustrates how Stoke Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Stoke Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Stoke Therapeutics Inc ranked by their cash flow conversion efficiency. Explore Stoke Therapeutics Inc (STOK) cash earnings ratio to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Ola Electric Mobility Ltd
NSE:OLAELEC
|
-0.066x |
|
Stanmore Resources Ltd
AU:SMR
|
0.133x |
|
Trident Digital Tech Holdings Ltd American Depository Shares
NASDAQ:TDTH
|
0.724x |
|
Australian United Investment Company Ltd
AU:AUI
|
0.021x |
|
Devyani International Limited
NSE:DEVYANI
|
0.095x |
|
Rendong Holdings Co Ltd
SHE:002647
|
0.057x |
|
City Union Bank Limited
NSE:CUB
|
-0.382x |
|
Dalian Zeus Entertainment
SHE:002354
|
-0.005x |
Annual Cash Flow Conversion Efficiency for Stoke Therapeutics Inc (2017–2025)
The table below shows the annual cash flow conversion efficiency of Stoke Therapeutics Inc from 2017 to 2025. View STOK stock price and chart for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $352.46 Million | $45.59 Million | 0.129x | +134.10% |
| 2024-12-31 | $229.02 Million | $-86.85 Million | -0.379x | +25.36% |
| 2023-12-31 | $159.56 Million | $-81.07 Million | -0.508x | -194.71% |
| 2022-12-31 | $184.85 Million | $-31.87 Million | -0.172x | +43.89% |
| 2021-12-31 | $217.78 Million | $-66.91 Million | -0.307x | -108.17% |
| 2020-12-31 | $286.08 Million | $-42.22 Million | -0.148x | -6.66% |
| 2019-12-31 | $224.43 Million | $-31.05 Million | -0.138x | -32.60% |
| 2018-12-31 | $105.07 Million | $-10.96 Million | -0.104x | -102.50% |
| 2017-12-31 | $-1.29 Million | $-5.38 Million | 4.167x | -- |
About Stoke Therapeutics Inc
Stoke Therapeutics, Inc. engages in the development of treatments for severe genetic diseases by upregulating protein expression. The company utilizes its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO) approach in developing antisense oligonucleotides (ASOs) to selectively restore protein levels. Its lead product candidates include STK-002, which is in Phase 1 clinical trials fo… Read more